Study Details
Testing COMP 360 Drug in Adults with Treatment-Resistant Depression
(IRB#: IRB_00159931)
Treatment-resistant depression (TRD) is when a person receives help for depression such as therapy with a physiatrist and taking an anti-depression drug, but depression keeps coming back. The study wants to investigate the efficacy and safety of COMP 360 for treatment resistant depression. People in this study will be randomly chosen for COMP 360 doses: 1mg, 10mg, and 25mg. The drug is taken as a swallowed pill. Being in the study requires participation for 55 to 62 weeks. Participants will attend clinic visits in person at a University of Utah Treatment-Resistant Mood Disorders clinic. Medical tests will be done during the study to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Unpaid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages18 years and older
- Diagnosis of Major Depressive Disorder
- Failure to respond to 2-4 different antidepressant medications for the current depressive episode
- Willing to taper off from antidepressants currently taking
Exclusion Criteria
- Bipolar disorder
- History of psychotic disorder (schizophrenia, schizoaffective disorder)
- Alcohol or substance use disorder over the last 12 months
- Pregnancy or breastfeeding
- History of stroke, heart attack, seizure, or uncontrolled high blood pressure.
Will I be paid for my time?
No
IRB#: IRB_00159931
PI: Brian Mickey
Department: PSYCHIATRY
Approval Date: 2024-02-21 07:00:00
Study Categories: Mental Health and Well-being Studies
Specialties: Psychiatry
I am Interested